Date post: | 01-Jan-2016 |
Category: |
Documents |
Upload: | phebe-dennis |
View: | 215 times |
Download: | 2 times |
Evaluation of the efficacy of one dose of autogenous MJPRRS vaccine in
nursery pigs
Dr. Mark Wagner, DVMFairmont Veterinary Clinic
Fairmont, MN
Purpose of study
• Gain a better understanding of the role and efficacy of using the autogenous MJPRRS vaccine in controlling or managing PRRS virus
Trial data to be presented
• Trial #1– Vaccination of PRRS naïve pigs at 21 days of age
and challenge with field virus at 32 days post vaccination
• Trial #2– Similar repeat of trial #1, pigs challenged at 28
days post vaccination
• Trial #3– Vaccination of PRRS viremic pigs at peak viremia
Trial design
• Challenge material– Virulent field virus with a 1-18-2 RFLP
• Group D-4 under MJPRRS virus grouping system
• Preparation of virus material– A 21 day old PRRS naïve pig inoculated with the 1-18-2 field virus– Serum collected 5 days post inoculation and frozen– An aliquot of serum inoculated on cell culture and
harvested 7 days later, then frozen
Trial design
• Analysis of challenge material– Sequencing completed to confirm 1-18-2 virus– Quantitative PRRS PCR’s completed along with
TCID50’s
Inoculum material
ORF6-copies per ml
Calculated IVP’s per ml TCID50
Serum 109 2,341 102
Cell Culture 1010 24,416 103
Trial design
• Challenge dose– Trial #1• 0.5ml IM plus 0.5ml IN (serum material = 100 viruses) (culture material = 1,000 viruses)
– Trial #2• 0.5ml IM plus 0.5ml IN (culture material = 1,000 viruses)
– Trial #3• 0.05ml IM plus 0.5ml IN (serum material = 55 viruses)
Trial design
• Vaccination protocol– Treatment group• MJPRRS
– 2ml dose that included 10% extra adjuvant (final 20%)
• Mycoplasma – 2ml dose
– Control groups• Mycoplasma
– 2ml dose
Trial design
• Data collection included– Body temperature– Virus replication based on PRRS Q-PCR’s– Mortality– Average daily gain weight
Summary PRRS virus replication in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to
a field virus at 53 and 49 days old (Trial #1 & #2 data)
Serum Challenged Culture Challenged
Days Post Challenge
Vaccinated Non–Vaccinated Vaccinated Non–Vaccinated
ORF6 copies* IVP# ORF6 copies IVP ORF6 copies IVP ORF6 copies IVP
51.8 x 109 704 2.8 x 109 1,118 1.3 x 109
--------------9.3 x 108
674-----------
367
2.2 x 109
---------------8.4 x 108
867----------
328
116.4 x 107 25 2.7 x 108 106 1.1 x 108
--------------4.2 x 107
44-----------
16
2.1 x 108
---------------7.2 x 107
83----------
28
235.4 x 105 0.21 2.0 x 106 0.79 2.2 x 106
--------------5.1 x 106
0.88-----------
1.9
1.4 x 106
---------------2.1 x 106
0.50----------
0.80
* ORF6 Copies per ml by Quantitative PCR# Infective Virus Particles calculated per ml based on Q-PCR
Summary of PRRS virus replication in 26 day old PRRS viremic pigs vaccinated with MJPRRS vaccine at the peak of viremia
compared to non-vaccinated controls (Trial #3 data)
Serum Challenged then Vaccinated Non-Vaccinated
ORF6 Copies* IVP# ORF6 Copies IVP
5 Days post challenge(Day of vaccination) 3.5 x 109 1,355 3.3 x 109 1,144
7 Days post challenge(2 Days post vaccination) 5.2 x 109 2,079 5.6 x 109 2,215
14 Days post challenge(7 Days post vaccination) 3.5 x 108 103 1.2 x 109 488
24 Days post challenge(10 Days post vaccination) 1.8 x 108 55 5.5 x 108 123
* ORF6 Copies per ml by Quantitative PCR# Infective Virus Particles calculated per ml based on Q-PCR
Summary of Average Daily Gain (ADG) performance in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to a field strain of
PRRS at 53 days of age (Trial #1 data)
Day 1 Day 32 post arrival Day 55 post arrival Overall
Day of Vaccination Challenged* Day 1-23 post challenge Day 1-55 arrival
Weight (Ibs) Average Average ADG Average ADG# ADG
Vaccinated 14.5 36.5 0.71 54.0 0.76 0.74
Non-Vaccinated 16.0 32.5 0.53 53.0 0.89 0.68
* All pigs challenged with PRRSv at 32 days post arrival (53 days of age)# ADG affected by mortality;
Vaccinated group, 1 of 22 dead Non-vaccinated group, 4 of 22 dead
Summary of Average Daily Gain (ADG) performance in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to a field strain of PRRS at 49 days of age
(Trial #2 data)
Day 1 Day 28 post arrival
Day 40 post arrival Day 54 post arrival Overall
Day of Vaccination Challenged* Day 1 – 11 post challenge
Day 11 – 24 post challenge
Day 1-54 arrival
Weight (Ibs) Average# Average ADG Average ADG Average ADG ADG
Vaccinated 13.7 31.2 0.62 34.2 0.27 49.0 1.14 0.74
Non-vaccinated 14.2 35.5 0.76 37.6 0.19 48.0 0.80 0.52
* All pigs challenged with PRRSv at 28 days post arrival (49 days of age)
Summary of Mortality in MJPRRS vaccinated compared to non-vaccinated 21 day old pigs when challenged to a field strain of
PRRS at 53 or 49 days of age (Trial #1 and #2 data)
Trial #1Challenge material Treatment group Mortality at 23 days post challenge
SerumNon-Vaccinated 3 of 11 (27%)
Vaccinated 1 of 11 (9%)
CultureNon-Vaccinated 1 of 11 (9%)
Vaccinated 0 of 11 (0%)
Trial # 2Challenge material Treatment group Mortality at 23 days post challenge
CultureNon-Vaccinated 0 of 16 (0%)
Vaccinated 0 of 16 (0%)
Overall mortality for non-vaccinated groups, 18.2%Overall mortality for vaccinated groups, 4.5%
Summary of Mortality in 26 day old PRRS viremic pigs vaccinated with MJPRRS vaccine at peak viremia compared to non-
vaccinated controls (Trial #3 data)
Trial # 3Challenge material Treatment group Mortality at 10 days post vaccination*
SerumNon-Vaccinated 3 of 12 (25%)
Vaccinated 2 of 12 (16%)
* 15 days post challenge
Summary (I)
• Virus Replication– For trial #1, a statistical reduction in virus replication
shown between the MJPRRS vaccinates compared to the non-vaccinates at days 5 and 11 post challenge (p value = 0.04 and 0.0098, respectively)
– For trial #2, no statistical difference noted
– For trial #3, a statistical reduction in virus replication during vaccination at peak viremia at day 7 and 10 post vaccination (p value = 0.048 and 0.002, respectively)
Summary (II)
• Average Daily Gain (ADG)– For trial #1, no statistical difference noted
Numerically: Vaccinates, Day 1-23 post challenge, 0.76 Non-Vaccinates, Day 1-23 post challenge, 0.89
High mortality in non-vaccinates likely affected ADG differences in calculation
– For trial #2, A statistical difference (p value = 0.026)between MJPRRS vaccinated group vs. controls during Day 1-24 Numerically: Vaccinates, Day 1-24 post challenge, 0.74 Non-Vaccinates, Day 1-24 post challenge, 0.52
Summary (III)• Mortality– For trial #1• Vaccinates = 1 of 22 (4.5%)• Non Vaccinates = 4 of 22 (18%)
– For trial #2• No mortality in either group
– For trial #3• Vaccinates = 2 of 12 (16%)• Non Vaccinates = 3 of 12 (25%)
Conclusions• Data demonstrated that PRRS naïve or viremic pigs
were able to respond to one dose of autogenous MJPRRS vaccine with extra adjuvant.
• A reduction on virus replication was statistically demonstrated (2 of 3 trials).
• A numerical improvement in ADG was demonstrated (2 of 2 trials). A statistical difference noted also (1 of 2 trials).
• A numerical improvement in Mortality was demonstrated (2 of 3 trials).